COPD

MD IQ

From the Journals

Triple-therapy cuts COPD exacerbations

The combination of an inhaled long-acting beta2-agonist, long-acting muscarinic antagonist, and glucocorticoid may reduce moderate to severe...

News from the FDA/CDC

FDA approves starting dose of roflumilast

Taking a smaller dose of a drug currently used to treat COPD may prevent patients from discontinuing their use of the larger therapeutic dose.

Pages